2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 1991, 115(5): 343-349.
[3]
3. Ryerson CJ, Nayar S, Swiston JR, et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res, 2010, 11(1): 12.
[4]
4. Bogaard HJ, Abe K, Vonk Noordegraaf A, et al. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest, 2009, 135(3): 794-804.
[5]
5. Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med, 2008, 178(6): 558-564.
[6]
6. Humbert M, Hoeper MM. Severe pulmonary arterial hypertension: a forme fruste of cancer? Am J Respir Crit Care Med, 2008, 178(6): 551-552.
[7]
7. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol, 2008, 44(1): 14-30.
[8]
8. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest, 2005, 127(4): 1446-1452.
[9]
9. Wilkins MR, Ali O, Bradlow W, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med, 2010, 181(10): 1106-1113.
[10]
10. Zhao L, Sebkhi A, Ali O, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J, 2009, 34(4): 948-957.
12. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation in present in primary but not second pulmonary hypertension. J Clin Invest, 1998, 101(5):927-934.
[13]
13. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol, 2009, 297(6): 1013-1032.
[14]
14. Jasmin JF, Lucas M, Cernacek P, et al. Effectiveness of a nonselective ETA/B and a selective ETA antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation, 2001, 103(2): 314-318.
[15]
15. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol, 1981, 240(2): 149-155.
[16]
16. Lappin PB, Ross KL, King LE, et al. The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo. Toxicol Appl Pharmacol, 1998, 150(1): 37-48.
[17]
17. Toya SP, Malik AB. Role of endothelial injury in disease mechanisms and contribution of progenitorcells in mediating endothelial repair. Immunobiology, 2012, 217(5): 569-580.
[18]
18. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med, 2005, 172(8):987-993.
[19]
19. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol, 2007, 46(1): 1-9.
[20]
20. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med, 2002, 166(10):1403-1408.
[21]
21. Balakumar P, Kathuria S, Taneja G, et al. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol, 2012, 52(1): 83-92.
[22]
22. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the proteinkinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000, 6(9): 1004-1010.
[23]
23. Plenz GA, Hofnagel O, Robenek H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation, 2004, 109(2): e7-e8.
[24]
24. Degraeve F, Bolla M, Blaie S, et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem, 2001, 276(50): 46849-46855.
[25]
25. Hernández-Perera O, Pérez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998, 101(12):2711-2719.
[26]
26. Mraiche F, Cena J, Das D, et al. Effects of statins on vascular function of endothelin-1. Br J Pharmacol, 2005, 144(5):715-726.
[27]
27. Wilson SH, Hermann J, Lerman LO, et al. Simvastatin preserves the structure of coronary adventitiaI vasa vasorum in experimental hypercholsterolemia independent of lipid 1owering. Circulation, 2002, 105(4):415-418.
[28]
28. Schafer M, Schafer C , Ewald N, et al. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ Res, 2003, 92(9):1010-1015.
34. Li M, Liu Y, Dutt P, et al. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol, 2007, 293(2): 463-471.
[31]
35. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003, 108(13):1640-1645.
[32]
36. Cheng G, Shan J, Xu G, et al. Apoptosis induced by simvastatin in rat vascular smooth muscle cell through Ca2+-calpain and caspase-3 dependent pathway. Pharmacol Res, 2003, 48(6):571-578.
[33]
37. 陆慰萱, 王辰. 肺循环病学. 北京:人民卫生出版社, 2007, 89-103.
[34]
38. Hauck L, Harms C, Grothe D, et al. Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circ Res, 2007, 100(1): 50-60.
[35]
30. Kaneta S, Satoh K, Kano S, et al. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis. 2003, 170(2):237-243.
[36]
31. Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett, 2001, 495(3):159-166.
[37]
32. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methyl-glutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999, 274(31):21926-21931.
[38]
33. Sindermann JR, Fan L, Weigle KA, et al. Differences in the effects of the HMG- CoA reductase inhibitors on proliferation and viability of smooth muscIe cells in culture. Atherosclerosis, 2000, 150(2):331-341.
